These targets include: MEF2C, a gene known to play a critical role in cardiovascular development and cardiac hypertrophy; CDK6, a member of the cyclin D signaling pathway the inhibition of which impairs cardiac hypertrophy in both in vitro and in vivo; and TLCD2, a gene identified in GWAS Ophiopojaponin-C analysis as a strong candidate associated with LV mass. Further investigation needs to be performed on these novel miRNAs to elucidate their potential role in the regulation of cardiac hypertrophy. To summarize, left ventricular hypertrophy remains a major risk factor for cardiovascular disease. Due to the limitations in the availability of cardiac tissue and the documented differences between human and animal models, hiPSC-CMs provide a viable alternative to study cardiac disease in humans. However, the use of iPSC derived cells is significantly governed by the disease of interest. For example, in case of a complex phenotype like cardiac hypertrophy, besides mimicing the genetic aspect, it is Gypenoside-XVII imperative to regulate the extrinsic, non-genetic component of the disease process. Using a cardiac hypertrophy stimulant like ET-1 instead of patient specific cell lines gives us the opportunity to establish an unbiased model to focus on identifying the underlying molecular pathways that help regulate the disease mechanism. Once established, we can use this model to perform future studies to focus on patient specific regulation of the disease process. With current treatment options limited, miRNAs provide a new class of potential therapeutic targets. In this study, we provide the first comprehensive RNA expression dataset for a hiPSC-derived cardiomyocyte model of cardiac hypertrophy. While our method of recapitulating the disease phenotype using ET-1 captures only a subset of the complex cardiac hypertrophy disease mechanism, it provides significant insights into hypertrophic regulatory pathways. Utilizing hiPSC-CMs and comparing our expression results to both animal models and human biopsies allows us to take the next step in identifing novel miRNAs and gene targets that may play a role in human disease. The intracellular protozoan parasite Toxoplasma gondii is a ubiquitous pathogen of warm-blooded animals with approximately one to two billion humans infected.